BRAF and cancer: Combination therapies using BRAF inhibitors and drugs that block them at different points within or upstream of the MAPK pathway, specifically MEK and EGFR inhibitors, have become standard cancer treatments for patients with BRAFV600 mCRC since the discovery of an adaptive feedback reactivation loop of MAPK signaling that sustains the activation of MAPK upon the inhibition of BRAF.